NCT00976456CompletedPhase 3
Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer
PD Dr. med. Wolfgang Schuette1 site in 1 country271 target enrollmentStarted: September 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 271
- Locations
- 1
- Primary Endpoint
- Progression Free Survival
Study Overview
Brief Summary
Multi-center, open, randomized (parallel) and comparative phase III.
Eligible patients will receive bevacizumab + chemotherapy for a minimum of 4 cycles followed by bevacizumab (+ pemetrexed, if appropriate) maintenance therapy until disease progression.
Arm A: Bevacizumab + pemetrexed
Arm B: Bevacizumab + pemetrexed + carboplatin
Detailed Description
Primary:
- Proof of non-inferior efficacy of a monochemotherapy regimen of pemetrexed plus bevacizumab versus a combination chemotherapy regimen of pemetrexed-carboplatin plus bevacizumab in elderly patients(> 65 years) as first-line treatment of advanced metastatic or recurrent non-squamous NSCLC by progression free survival
Secondary:
- To assess the efficacy of bevacizumab as measured by overall response rate and overall survival.
- To assess the safety of bevacizumab in combination with pemetrexed and pemetrexed and carboplatin.
- To assess quality of life by EORTC questionnaire QLQ-C30 and its lung cancer module LC-13
- To assess activity of daily life (iADL) in relation to ECOG performance status prior to study treatment
- To assess patient's outcome and treatment delivery in relation to the Charlson comorbidity score and the Simplified Comorbidity Score
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 65 Years to — (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Stage IIIb and IV NSCLC, excluded squamous cell NSCLC
- •Age ≥ 65 years
Exclusion Criteria
- •Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component
- •History of haemoptysis
- •Evidence of tumour invading major blood vessels on imaging
- •Radiotherapy within 28 days prior to enrolment
- •Patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)
- •Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed
- •Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6 months before enrolment), myocardial infarction (≤6 months before enrolment), unstable angina, CHF NYHA Class ≥II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
- •Non-healing wound, active peptic ulcer or bone fracture
- •History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment
Arms & Interventions
Bevacizumab + Pemetrexed
Active Comparator
Bevacizumab + Pemetrexed
Intervention: Bevacizumab + Pemetrexed (Drug)
Bevacizumab + Pemetrexed + Carboplatin
Active Comparator
Bevacizumab + Pemetrexed + Carboplatin
Intervention: Bevacizumab + Pemetrexed + Carboplatin (Drug)
Outcomes
Primary Outcomes
Progression Free Survival
Time Frame: 42 months
Progression free survival (defined as the number of days from the day of the first treatment until day of death (from any cause) or progression, whichever occurs earlier, or until the day of the last response assessment, if no progression or death (from any cause) is observed during the study).
Secondary Outcomes
- Overall Survival(42 months)
Investigators
PD Dr. med. Wolfgang Schuette
PhD MD
Martha-Maria Krankenhaus Halle-Dölau gGmbH
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLCUnresectable Malignant NeoplasmNon-small Cell Lung CancerNCT01963351University of Athens150
Completed
Phase 3
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)Non-Squamous Non-Small Cell Lung CancerNCT01351415Hoffmann-La Roche485
Completed
Phase 3
A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal CancerColorectal CancerNCT00484939Hoffmann-La Roche280
Completed
Phase 4
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast CancerBreast CancerNCT01094184Hoffmann-La Roche49
Completed
Phase 2
A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.SarcomaNCT00643565Hoffmann-La Roche154